Recombinant Staphylococcus aureus Uncharacterized protein SAS0302 (SAS0302)

Shipped with Ice Packs
In Stock

Description

Overview of Recombinant Staphylococcus aureus Uncharacterized Protein SAS0302 (SAS0302)

Staphylococcus aureus is a significant human pathogen known for causing a variety of infections, particularly those associated with implanted medical devices. Biofilm formation, where bacteria attach to surfaces and create multilayered cell clusters, is a critical factor in these infections . Protein factors, including surface proteins, play a crucial role in biofilm accumulation .

SAS0302, also known as Staphylococcus aureus surface protein C (SasC), is a protein that was, at the time of its discovery, an uncharacterized surface protein found in S. aureus . Research has shown that SasC is involved in cell aggregation and biofilm formation, which are important for the colonization during infection .

Experimental Studies and Findings

sasC was heterologously expressed in Staphylococcus carnosus, resulting in the formation of significant cell aggregates, which indicates intercellular adhesion and biofilm accumulation . Further experiments revealed that:

  • Expression of sasC in S. carnosus and S. aureus led to enhanced biofilm formation .

  • The N-terminal domain of SasC was localized as the region conferring cell aggregation and biofilm formation .

  • SasC does not mediate binding to fibrinogen, thrombospondin-1, von Willebrand factor, or platelets .

Role in Biofilm Formation

SasC contributes to the process of biofilm formation in S. aureus. Biofilms are complex communities of microorganisms that adhere to surfaces, making them resistant to antibiotics and host immune responses . SasC's involvement in cell aggregation and biofilm accumulation suggests it plays a crucial role in the early stages of biofilm development, facilitating bacterial adhesion and the formation of multilayered cell clusters .

Implications for Implant-Associated Infections

S. aureus is a major cause of implant-associated infections, where bacteria colonize implanted medical devices, leading to persistent and difficult-to-treat infections . Given SasC's role in biofilm formation, it may be a potential target for therapeutic interventions aimed at preventing or disrupting biofilm development on medical implants .

Potential Therapeutic Applications

Understanding the function and mechanisms of proteins like SasC may lead to the development of new strategies to combat S. aureus infections. Potential therapeutic applications could include:

  • Developing inhibitors that target SasC to prevent cell aggregation and biofilm formation.

  • Designing novel surface coatings for medical implants that interfere with SasC-mediated adhesion.

  • Creating immunotherapeutic approaches that target SasC to enhance the host immune response against S. aureus biofilms.

Tables Summarizing Key Data

FeatureDescription
Gene Size6558 nucleotides
Protein Size2186 amino acids
Molecular Mass237.9 kDa
Key DomainsN-terminal signal peptide, C-terminal LPXTG cell wall anchorage motif, repeat region with 17 repeats similar to DUF1542
Theoretical pI Value5.08
Amino Acid Composition25.1% hydrophobic, 12.1% basic, 13.2% acidic
FunctionInvolved in cell aggregation and biofilm formation
Binding PropertiesDoes not mediate binding to fibrinogen, thrombospondin-1, von Willebrand factor, or platelets
Expression inStaphylococcus carnosus, Staphylococcus aureus
Effect of Heterologous ExpressionFormation of cell aggregates, enhanced biofilm formation

Homology with Other Proteins

Strain% Identity with SasC
S. aureus MW297%
S. aureus MSSA47697%
S. aureus USA30096%
S. aureus COL96%
S. aureus Newman96%
S. aureus NCTC832596%
S. aureus N31596%
S. aureus MRSA25289%

Product Specs

Form
Lyophilized powder
Note: While we prioritize shipping the format currently in stock, please specify your format preference in order notes for customized fulfillment.
Lead Time
Delivery times vary depending on purchasing method and location. Please consult your local distributor for precise delivery estimates.
Note: Standard shipping includes blue ice packs. Dry ice shipping requires prior arrangement and incurs additional charges.
Notes
Avoid repeated freeze-thaw cycles. Store working aliquots at 4°C for up to one week.
Reconstitution
Centrifuge the vial briefly before opening to consolidate contents. Reconstitute the protein in sterile, deionized water to a concentration of 0.1-1.0 mg/mL. For long-term storage, we recommend adding 5-50% glycerol (final concentration) and aliquoting at -20°C/-80°C. Our standard glycerol concentration is 50% and serves as a guideline.
Shelf Life
Shelf life depends on storage conditions, buffer composition, temperature, and protein stability. Generally, liquid formulations have a 6-month shelf life at -20°C/-80°C, while lyophilized forms have a 12-month shelf life at -20°C/-80°C.
Storage Condition
Upon receipt, store at -20°C/-80°C. Aliquoting is crucial for multiple uses. Avoid repeated freeze-thaw cycles.
Tag Info
Tag type is determined during manufacturing.
The tag type is determined during production. To request a specific tag, please inform us, and we will prioritize its development.
Synonyms
SAS0302Protein-ADP-ribose hydrolase; EC 3.2.1.-
Buffer Before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Datasheet
Please contact us to get it.
Expression Region
1-266
Protein Length
full length protein
Purity
>85% (SDS-PAGE)
Species
Staphylococcus aureus (strain MSSA476)
Target Names
SAS0302
Target Protein Sequence
METLKSNKAR LEYLINDMHR ERNDNDVLVM PSSFEDLWEL YRGLANVRPA LPVSDEYLAV QDAMLSDLNR QHVTDLKDLK PIKGDNIFVW QGDITTLKID AIVNAANSRF LGCMQANHDC IDNIIHTKAG VQVRLDCAEI IRQQGRNEGV GKAKITRGYN LPAKYIIHTV GPQIRRLPVS KMNQDLLAKC YLSCLKLADQ HSLNHVAFCC ISTGVFAFPQ DEAAEIAVRT VESYLKETNS TLKVVFNVFT DKDLQLYKEA FNRDAE
Uniprot No.

Target Background

Function
This protein specifically reverses SirTM-mediated mono-ADP-ribosylation of GcvH-L by releasing ADP-ribose from the target protein. It may also modulate the response to host-derived oxidative stress.
Database Links

KEGG: sas:SAS0302

Q&A

How should I design my initial expression system for recombinant SAS0302 protein?

When expressing recombinant S. aureus proteins, the experimental design should account for potential toxic effects on the host system and codon optimization requirements. Based on established protocols for similar S. aureus surface proteins, consider the following approach:

  • Start with E. coli BL21(DE3) as your expression system for initial characterization studies

  • Compare several expression vectors (pET, pGEX, pMAL) with different fusion tags (His, GST, MBP)

  • Test multiple induction conditions using a factorial design

The experimental design for expression optimization should be structured as follows:

Expression ParameterTested ConditionsNumber of Levels
Temperature16°C, 25°C, 37°C3
IPTG Concentration0.1 mM, 0.5 mM, 1.0 mM3
Induction Time4h, 8h, overnight3
Host StrainBL21(DE3), Rosetta, Origami3

Similar to the simulation project methodology for experimental design, data collection would involve one observation for each treatment group, with variables specifying the levels of factor variables . Protein yield and solubility should be assessed for each condition to determine optimal expression parameters.

What are the best methods to confirm the identity of purified recombinant SAS0302?

Identity confirmation for recombinant SAS0302 should include multiple complementary approaches:

  • SDS-PAGE analysis coupled with western blotting using anti-tag antibodies

  • Mass spectrometry analysis (MALDI-TOF or LC-MS/MS)

  • N-terminal sequencing for the first 5-10 amino acids

  • Peptide mass fingerprinting after tryptic digestion

For protein sequence verification, compare experimental and theoretical data:

Verification MethodExpected ResultConfirmation Criteria
Intact Mass AnalysisTheoretical MW ±0.1%Mass within expected range for full-length protein with modifications
Peptide Coverage≥80% sequence coverageIdentification of unique peptides from different regions
N-terminal SequencingMatch to predicted sequenceConfirmation of proper processing and tag cleavage

This multi-method approach ensures reliable identification before proceeding with functional studies, similar to verification protocols used for other S. aureus surface proteins.

How can I predict the potential structural features of SAS0302 in the absence of crystallographic data?

For uncharacterized proteins like SAS0302, a hierarchical approach to structural prediction is recommended:

  • Begin with primary sequence analysis using multiple bioinformatics tools

  • Perform secondary structure prediction using consensus methods

  • Generate tertiary structure models using homology modeling or ab initio methods

  • Validate predicted structures using molecular dynamics simulations

Based on approaches used for other S. aureus surface proteins like SasG, consider looking for specific domain architectures:

Prediction ToolTarget FeatureInterpretation Guidelines
Pfam/SMARTConserved domainsIdentify domain boundaries and functional regions
TMHMM/SignalPTransmembrane/signal regionsPredict cellular localization
PSIPRED/JPredSecondary structure elementsMap β-sheets and α-helices
I-TASSER/AlphaFold3D structure modelAssess confidence scores for different regions

Recent structural studies of the SasG protein have revealed distinct lectin domains with varying binding specificities (SasG-I and SasG-II) . Similar approaches could be applied to SAS0302 to identify potential binding pockets or functional domains.

What comparative genomics approaches would be most informative for predicting SAS0302 function?

When investigating uncharacterized proteins like SAS0302, comprehensive comparative genomics can provide functional insights:

  • Perform sequence similarity searches across multiple bacterial species

  • Analyze genomic context and gene neighborhood conservation

  • Examine phylogenetic distribution across S. aureus strains

  • Search for co-evolution patterns with known functional partners

Similar to the phylogenetic analyses performed for SasG variants, where two major divergent alleles (SasG-I and SasG-II) were identified , you should:

Analytical ApproachImplementation MethodExpected Outcome
Ortholog IdentificationBLAST/OrthoMCLIdentification of related proteins across species
Synteny AnalysisMicrobesOnline/SyntTaxConservation of genomic context
Phylogenetic ProfilingConstructed from whole genome dataCo-occurrence patterns
Structural HomologyHHpred/Phyre2Distant functional relationships

The clonal complex distribution pattern observed for SasG variants could serve as a model for investigating SAS0302 distribution. This approach may reveal whether SAS0302, like SasG, shows strain-level diversity in gene presence, expression level, and function.

How can I design experiments to determine if SAS0302 plays a role in S. aureus adhesion to host cells?

To investigate potential adhesion functions of SAS0302, design a comprehensive experimental approach:

  • Generate clean deletion and complementation mutants of SAS0302

  • Perform adhesion assays with multiple cell types (epithelial, endothelial, immune cells)

  • Compare adhesion between wild-type, deletion mutant, and complemented strains

  • Test specific inhibitors or blocking antibodies against recombinant SAS0302

Drawing from studies on SasG-mediated adhesion to corneocytes , design your adhesion experiments as follows:

Experimental ApproachCell Types/SubstratesMeasurements
Static Adhesion AssayN/TERT keratinocytes, corneocytesCFU counts, fluorescence
Flow Cell AnalysisVarious cell monolayers under shear stressReal-time adhesion dynamics
AFM Force SpectroscopyPurified cell surface componentsSingle-molecule binding forces
Glycosidase TreatmentModified cell surfacesDependency on specific glycans

The recent finding that SasG-mediated adhesion can be recapitulated using differentiated N/TERT keratinocytes suggests this could be a valuable model system for testing SAS0302 function as well.

What are the most appropriate approaches for studying potential interactions between SAS0302 and other S. aureus virulence factors?

To investigate protein-protein interactions involving SAS0302:

  • Perform co-immunoprecipitation experiments with epitope-tagged SAS0302

  • Use bacterial two-hybrid or split-GFP systems for interaction screening

  • Implement surface plasmon resonance for quantitative binding analysis

  • Conduct genetic epistasis studies with double mutants

Design a systematic interaction screening approach:

Interaction MethodAdvantagesLimitationsData Analysis
Bacterial Two-HybridIn vivo detectionLimited to cytoplasmic interactionsColony selection and reporter quantification
Pull-down AssaysDirect physical interactionMay miss transient interactionsMS identification of binding partners
Crosslinking MSCaptures in vivo interactionsComplex data analysisXL-MS software algorithms
Functional EpistasisReveals genetic relationshipsIndirect evidence of interactionStatistical analysis of phenotypic data

Similar to the analysis of SasG lectin domain interactions with host factors , you could investigate whether SAS0302 shows specific binding to host glycans or other surface components.

How should I design experiments to determine the contribution of SAS0302 to S. aureus virulence in vivo?

For in vivo virulence studies of SAS0302, consider a multi-model approach:

  • Start with invertebrate infection models (G. mellonella, C. elegans)

  • Progress to murine infection models (skin, systemic, device-associated)

  • Compare wild-type, knockout, and complemented strains

  • Include relevant clinical isolates with variation in SAS0302 expression

Design your animal experiments with statistical power in mind:

Model SystemInfection RouteReadoutsStatistical Considerations
G. mellonella LarvaeDirect injectionSurvival, bacterial burdenKaplan-Meier analysis, n≥20 per group
Murine Skin InfectionSubcutaneousLesion size, histopathologyANOVA with repeated measures, n≥8 per group
Murine BacteremiaTail vein injectionSurvival, organ burdenLog-rank test, n≥10 per group
Ex vivo Human SkinSurface applicationPenetration, inflammatory responsePaired analysis, n≥6 donors

When designing these experiments, apply principles similar to those discussed in experimental design simulation projects, where you would specify factor variables and observation numbers for each treatment group .

What controls and validations are essential when performing RNA-seq to study SAS0302 regulation?

For RNA-seq studies focusing on SAS0302 regulation:

  • Include biological triplicates for each condition

  • Implement spike-in controls for normalization

  • Validate key findings with RT-qPCR

  • Confirm protein-level changes for major findings

Experimental design considerations:

Experimental ComponentRecommendationValidation Method
RNA ExtractionRIN score >8.0 for all samplesBioanalyzer quality control
Library PreparationStranded library preparationqPCR validation
Sequencing Depth>20 million reads per sampleSaturation analysis
Differential ExpressionFold change >2, FDR <0.05RT-qPCR of 10-15 selected genes

For data analysis, implement a factorial design approach similar to the experimental design methodology , treating different growth conditions, genetic backgrounds, or stimuli as factor variables with specified levels.

How can I integrate multiple omics datasets to better understand SAS0302 function in the context of S. aureus pathogenesis?

For multi-omics integration to understand SAS0302:

  • Combine transcriptomics, proteomics, and metabolomics data

  • Apply network analysis to identify functional modules

  • Use dimensionality reduction to visualize relationships

  • Implement machine learning for pattern recognition

Integration methodology:

Omics LayerAnalytical ApproachIntegration Strategy
TranscriptomicsDifferential expression analysisCorrelation with protein abundance
ProteomicsProtein interaction mappingNetwork construction with SAS0302 as focal point
MetabolomicsPathway enrichmentLinking metabolic changes to SAS0302 expression
PhenomicsGrowth/virulence phenotypingMulti-parameter correlation analysis

Similar to how researchers analyzed SasG variants across multiple S. aureus strains belonging to 39 clonal complexes , a comprehensive analysis of SAS0302 would benefit from integrating genomic, expression, and functional data across multiple strain backgrounds.

What are the key considerations when analyzing contradictory results between in vitro and in vivo studies of SAS0302?

When confronting contradictory results between different experimental systems:

  • Assess differences in experimental conditions that might explain discrepancies

  • Consider temporal dynamics of expression and regulation

  • Evaluate strain-specific variations in SAS0302 sequence or expression

  • Examine potential compensatory mechanisms in complex systems

Recommended approach for reconciling contradictory data:

Contradiction TypeInvestigation ApproachResolution Strategy
Expression Level DifferencesConfirm with multiple methodsTime-course analysis in different conditions
Phenotypic Impact VariationsControl for genetic backgroundGenerate mutations in multiple strain backgrounds
Binding Partner DiscrepanciesValidate with multiple interaction assaysContext-dependent interaction analysis
Structural Function ConflictsDomain-specific mutational analysisStructure-function correlation studies

This approach parallels the discovery that SasG has evolved multiple variants (SasG-I and SasG-II) with different binding specificities , suggesting that SAS0302 might similarly have context-dependent functions that explain apparently contradictory results.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.